Drug Combination Details
| General Information of the Combination (ID: C61675) | |||||
|---|---|---|---|---|---|
| Name | Vincristine NP Info | + | Belinostat Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Diffuse B-cell lymphoma
[ICD-11: 2A81]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BCL2L11 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | MCL1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | SU-DHL-4 | CVCL_0539 | B-cell lymphoma | Homo sapiens | ||
| DB | CVCL_1168 | B-cell lymphoma | Homo sapiens | |||
| OCI-Ly19 | CVCL_1878 | B-cell lymphoma | Homo sapiens | |||
| SU-DHL-8 | CVCL_2207 | B-cell lymphoma | Homo sapiens | |||
| GM18564 | CVCL_P179 | Healthy | Homo sapiens | |||
| Experimental
Result(s) |
Vincristine sensitizes DLBCL cells to the cytotoxic effects of belinostat. | |||||
